Drug Approval | September 16, 2025
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments
Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)
The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m
APF Futurity is made from polyolefin materials with no metal parts or recycling disruptors
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
Subscribe To Our Newsletter & Stay Updated
